130 related articles for article (PubMed ID: 24460070)
1. A method to estimate composite doses for organs at risk in prostate cancer patients treated with EBRT in combination with HDR BT.
Pettersson N; Johansson KA; Alsadius D; Tucker SL; Steineck G; Olsson C
Acta Oncol; 2014 Jun; 53(6):815-21. PubMed ID: 24460070
[TBL] [Abstract][Full Text] [Related]
2. Patient's specific integration of OAR doses (D2 cc) from EBRT and 3D image-guided brachytherapy for cervical cancer.
Gelover E; Katherine C; Mart C; Sun W; Kim Y
J Appl Clin Med Phys; 2018 Mar; 19(2):83-92. PubMed ID: 29349933
[TBL] [Abstract][Full Text] [Related]
3. Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications.
Moulton CR; House MJ; Lye V; Tang CI; Krawiec M; Joseph DJ; Denham JW; Ebert MA
Radiat Oncol; 2016 Oct; 11(1):144. PubMed ID: 27799048
[TBL] [Abstract][Full Text] [Related]
4. Accumulation of rectum dose-volume metrics for prostate external beam radiotherapy combined with brachytherapy: Evaluating deformably registered dose distribution addition using parameter-based addition.
Moulton CR; House MJ; Lye V; Tang CI; Krawiec M; Joseph DJ; Denham JW; Ebert MA
J Med Imaging Radiat Oncol; 2017 Aug; 61(4):534-542. PubMed ID: 28185419
[TBL] [Abstract][Full Text] [Related]
5. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
6. Comparison of different contouring definitions of the rectum as organ at risk (OAR) and dose-volume parameters predicting rectal inflammation in radiotherapy of prostate cancer: which definition to use?
Nitsche M; Brannath W; Brückner M; Wagner D; Kaltenborn A; Temme N; Hermann RM
Br J Radiol; 2017 Feb; 90(1070):20160370. PubMed ID: 27936891
[TBL] [Abstract][Full Text] [Related]
7. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
[TBL] [Abstract][Full Text] [Related]
8. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.
Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653
[TBL] [Abstract][Full Text] [Related]
9. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
10. The influence of a rectal ultrasound probe on the separation between prostate and rectum in high-dose-rate brachytherapy.
Rylander S; Buus S; Bentzen L; Pedersen EM; Tanderup K
Brachytherapy; 2015; 14(5):711-7. PubMed ID: 26164752
[TBL] [Abstract][Full Text] [Related]
11. Assessment of HDR brachytherapy-replicating prostate radiotherapy planning for tomotherapy, cyberknife and VMAT.
de Chavez R; Grogan G; Hug B; Howe K; Grigg A; Waterhouse D; Lane J; Glyde A; Brown E; Bydder S; Pryor D; Hargrave C; Charles PH; Hellyer J; Ebert MA
Med Dosim; 2022 Spring; 47(1):61-69. PubMed ID: 34551879
[TBL] [Abstract][Full Text] [Related]
12. Three-dimensional dose addition of external beam radiotherapy and brachytherapy for oropharyngeal patients using nonrigid registration.
Vásquez Osorio EM; Hoogeman MS; Teguh DN; Al-Mamgani A; Kolkman-Deurloo IK; Bondar L; Levendag PC; Heijmen BJ
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1268-77. PubMed ID: 21129854
[TBL] [Abstract][Full Text] [Related]
13. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
14. High dose rate brachytherapy boost for prostate cancer: Biochemical control and the impact of transurethral resection of the prostate and hydrogel spacer insertion on toxicity outcomes.
Chao M; Bolton D; Lim Joon D; Chan Y; Lawrentschuk N; Ho H; Spencer S; Wasiak J; Guerrieri M; Ow D; Troy A; Pham T; Sengupta S; Tan A; McMillan K; Koufogiannis G; Foroudi F; Ng M; Khoo V
J Med Imaging Radiat Oncol; 2019 Jun; 63(3):415-421. PubMed ID: 30908894
[TBL] [Abstract][Full Text] [Related]
15. Determining DVH parameters for combined external beam and brachytherapy treatment: 3D biological dose adding for patients with cervical cancer.
Van de Kamer JB; De Leeuw AA; Moerland MA; Jürgenliemk-Schulz IM
Radiother Oncol; 2010 Feb; 94(2):248-53. PubMed ID: 20080309
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH
Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848
[TBL] [Abstract][Full Text] [Related]
17. A feasibility study of using advanced external beam techniques to create a vaginal cuff brachytherapy-like endometrial boost plan.
Grelewicz Z; Zerrusen B; Sathiaseelan V; Zhang H
Med Dosim; 2018 Spring; 43(1):30-38. PubMed ID: 28886961
[TBL] [Abstract][Full Text] [Related]
18. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
19. Adaptive image guided brachytherapy for cervical cancer: a combined MRI-/CT-planning technique with MRI only at first fraction.
Nesvacil N; Pötter R; Sturdza A; Hegazy N; Federico M; Kirisits C
Radiother Oncol; 2013 Apr; 107(1):75-81. PubMed ID: 23068712
[TBL] [Abstract][Full Text] [Related]
20. Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate.
Hermesse J; Biver S; Jansen N; Lenaerts E; Nickers P
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):269-76. PubMed ID: 19775833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
